---
document_datetime: 2024-12-04 11:15:26
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/scintimun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: scintimun-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.9630077
conversion_datetime: 2025-12-24 07:55:39.594351
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Scintimun

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                          | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                  |
|----------------------|------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/385/2 02401    | Periodic Safety Update EU Single assessment - besilesomab                                      | 19/09/2024                          | 22/11/2024                                  | Annex II                         | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/385/202401. |
| IB/0016              | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation | 12/12/2022                          | 08/02/2024                                  | SmPC, Labelling and              |                                                                                                                                          |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                              |            |            | PL   |                                   |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| II/0015           | Please refer to the Recommendations section above C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority                                              | 29/09/2022 | n/a        |      | Not applicable                    |
| PSUSA/385/2 01901 | Periodic Safety Update EU Single assessment - besilesomab                                                                                                                                                                                    | 05/09/2019 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0014           | B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate                                 | 14/05/2019 | n/a        |      |                                   |
| IA/0013           | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient | 03/04/2019 | n/a        |      |                                   |
| PSUSA/385/2 01701 | Periodic Safety Update EU Single assessment - besilesomab                                                                                                                                                                                    | 01/09/2017 | n/a        |      | PRAC Recommendation - maintenance |
| II/0010/G         | This was an application for a group of variations. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch                                              | 22/09/2016 | 06/02/2017 | SmPC |                                   |

<div style=\"page-break-after: always\"></div>

|                   | biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.b.5.z - Change to in-process tests or limits applied during the manufacture of the finished product - Other variation B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.e.1.a.3 - Change in immediate packaging of the finished product - Qualitative and quantitative composition - Sterile medicinal products and biological/immunological medicinal products B.II.e.4.c - Change in shape or dimensions of the container or closure (immediate packaging) - Sterile   |            |            |                           |                                   |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|---------------------------|-----------------------------------|
| PSUSA/385/2 01601 | Periodic Safety Update EU Single assessment - besilesomab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 02/09/2016 | n/a        |                           | PRAC Recommendation - maintenance |
| IB/0009           | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/02/2016 | 06/02/2017 | SmPC                      |                                   |
| IB/0007           | C.I.z - Changes (Safety/Efficacy) of Human and Veterinary Medicinal Products - Other variation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 28/01/2016 | 22/02/2016 | SmPC, Annex II, Labelling |                                   |

<div style=\"page-break-after: always\"></div>

|                   |                                                                                                                                                                                                                                                            |            |            | and PL                           |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/385/2 01501 | Periodic Safety Update EU Single assessment - besilesomab                                                                                                                                                                                                  | 09/07/2015 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| R/0005            | Renewal of the marketing authorisation.                                                                                                                                                                                                                    | 26/06/2014 | 26/08/2014 | SmPC, Annex II, Labelling and PL | The CHMP, having reviewed the available information on the status of the fulfilment of post-authorisation measures and having confirmed the positive benefit/risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of Scintimun, subject to the Conditions as laid down in Annex II to the Opinion. The CHMP recommends that the renewal be granted with unlimited validity. |
| PSUV/0004         | Periodic Safety Update                                                                                                                                                                                                                                     | 10/07/2014 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| IAIN/0003         | B.II.b.1.a - Replacement or addition of a manufacturing site for the FP - Secondary packaging site                                                                                                                                                         | 16/08/2012 | n/a        |                                  |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IG/0015           | C.I.9.e - Changes to an existing pharmacovigilance system as described in the DDPS - Changes in the major contractual arrangements with other persons or organisations involved in the fulfilment of pharmacovigilance obligations and described in the DD | 06/08/2010 | n/a        | Annex II                         |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |
| IB/0001           | B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition)                                                                                                                     | 23/07/2010 | n/a        | SmPC                             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |